Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $14.0 million.

  • Ocular Therapeutix's Non-Current Deffered Revenue changed 0.0% to $14.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $14.0 million for FY2025, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Non-Current Deffered Revenue is $14.0 million, which was down 0.0% from $14.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Non-Current Deffered Revenue high stood at $14.3 million for Q2 2023, and its period low was $12.0 million during Q1 2021.
  • In the last 5 years, Ocular Therapeutix's Non-Current Deffered Revenue had a median value of $14.0 million in 2024 and averaged $13.5 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 1277.5% in 2022, then crashed by 178.2% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Non-Current Deffered Revenue (Quarter) stood at $13.0 million in 2021, then rose by 2.98% to $13.4 million in 2022, then grew by 5.59% to $14.1 million in 2023, then decreased by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $14.0 million for Q4 2025, versus $14.0 million for Q3 2025 and $14.0 million for Q2 2025.